UK-US trade deal

Market Access

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.